These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33022649)

  • 1. Contemporary Population-Based Analysis of Bone Mineral Density Testing in Men Initiating Androgen Deprivation Therapy for Prostate Cancer.
    Hu J; Aprikian AG; Vanhuyse M; Dragomir A
    J Natl Compr Canc Netw; 2020 Oct; 18(10):1374-1381. PubMed ID: 33022649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate Cancer.
    Suarez-Almazor ME; Pundole X; Cabanillas G; Lei X; Zhao H; Elting LS; Lopez-Olivo MA; Giordano SH
    JAMA Netw Open; 2022 Apr; 5(4):e225432. PubMed ID: 35363269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer.
    Shahinian VB; Kuo YF
    J Gen Intern Med; 2013 Nov; 28(11):1440-6. PubMed ID: 23670565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
    Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy.
    Morgans AK; Smith MR; O'Malley AJ; Keating NL
    Cancer; 2013 Feb; 119(4):863-70. PubMed ID: 23065626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
    Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D.
    Alibhai SM; Mohamedali HZ; Gulamhusein H; Panju AH; Breunis H; Timilshina N; Fleshner N; Krahn MD; Naglie G; Tannock IF; Tomlinson G; Warde P; Duff Canning S; Cheung AM
    Osteoporos Int; 2013 Oct; 24(10):2571-9. PubMed ID: 23563932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
    Joseph JS; Lam V; Patel MI
    Eur Urol Oncol; 2019 Sep; 2(5):551-561. PubMed ID: 31411986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoporosis due to androgen deprivation therapy in men with prostate cancer.
    Daniell HW
    Urology; 2001 Aug; 58(2 Suppl 1):101-7. PubMed ID: 11502461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer.
    Ito K; Elkin EB; Girotra M; Morris MJ
    Ann Intern Med; 2010 May; 152(10):621-9. PubMed ID: 20479027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.
    Kiratli BJ; Srinivas S; Perkash I; Terris MK
    Urology; 2001 Jan; 57(1):127-32. PubMed ID: 11164157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen deprivation therapy for prostate cancer results in significant loss of bone density.
    Wei JT; Gross M; Jaffe CA; Gravlin K; Lahaie M; Faerber GJ; Cooney KA
    Urology; 1999 Oct; 54(4):607-11. PubMed ID: 10510915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention and management of osteoporosis in men receiving androgen deprivation therapy: a survey of urologists and radiation oncologists.
    Alibhai SM; Rahman S; Warde PR; Jewett MA; Jaffer T; Cheung AM
    Urology; 2006 Jul; 68(1):126-31. PubMed ID: 16844454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
    Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.
    Krupski TL; Smith MR; Lee WC; Pashos CL; Brandman J; Wang Q; Botteman M; Litwin MS
    Cancer; 2004 Aug; 101(3):541-9. PubMed ID: 15274067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer.
    Panju AH; Breunis H; Cheung AM; Leach M; Fleshner N; Warde P; Duff-Canning S; Krahn M; Naglie G; Tannock I; Tomlinson G; Alibhai SM
    BJU Int; 2009 Mar; 103(6):753-7. PubMed ID: 19007370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.
    Lang JM; Wallace M; Becker JT; Eickhoff JC; Buehring B; Binkley N; Staab MJ; Wilding G; Liu G; Malkovsky M; McNeel DG
    Clin Genitourin Cancer; 2013 Dec; 11(4):407-15. PubMed ID: 23835291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.
    Shao YH; Moore DF; Shih W; Lin Y; Jang TL; Lu-Yao GL
    BJU Int; 2013 May; 111(5):745-52. PubMed ID: 23331464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.